BCa19, held in Turin on 17-18 May, is set to bring together a lot of opinion leaders in bladder cancer who will be giving very practical talks and case-based discussions that will cover many aspects of BCa treatment relevant to everyday practice.
Prof. Peter Black lectures in the University of British Columbia Urologic Sciences Department and is Senior Research Scientist at the Vancouver Prostate Centre. At BCa19, he is set to give talks on new developments in non-immunological intravesical treatment, variant (aberrant) pathologies, and take part in the case discussions and panel discussions that make up a significant part of the scientific programme. Below, he gives his view on the most important future trends in bladder cancer treatment:
“Although the advances with immune checkpoint blockade have been a major breakthrough for patients with bladder cancer, we are really only seeing the tip of the iceberg here. The multitude of possibilities for combination therapies between the current batch of drugs and new checkpoint inhibitors, as well as between checkpoint inhibitors and other established (e.g. radiotherapy) treatments is dizzying.”
“I think we are going to see incremental increases in response rates and survival times with each successive round of trials, just as we have seen with kidney cancer. In the very near future we will likely be adopting these drugs in the first-line metastatic setting (perhaps in combination with cisplatin-based chemotherapy) and in the adjuvant setting after radical cystectomy. Also in these settings combination therapies will likely be most effective in the future.”
“Our endless search for clinically useful biomarkers is likely to come to fruition in the near future. Ongoing trials will likely show that the DNA damage repair genes, RNA-based molecular subtypes, or the COXEN algorithm (RNA expression-based platform to predict response to chemotherapy) can predict response to neoadjvunt chemotherapy, so that only patients likely to respond to chemo will receive it.”
“These markers may also allow us to determine whether some patients can preserve their bladder after neoadjuvant chemotherapy. Various urine markers are also looking very promising, with performance characteristics that will likely make them useful in the evaluation of patients with hematuria, and for surveillance of patients with a history of bladder cancer.”
BCa19 is part of the EAU’s Onco-Urology Update series, together with PCa19 and RCC19. These meetings are co-organised with the European School of Urology and offer delegates a compact and complete annual update on the latest treatment options. Pre- and post-meeting testing, interactive case discussions and expert faculty give these meetings a strong educational character. Online registration remains open until the end of May 9th.
In addition to the two-day scientific programme, delegates are also invited to join a separate, pre-meeting live surgery programme at the Molinette Hospital, free of charge. You can register for the live programme separately.